Clinical trials: Chronic Pulmonary Obstruction
Pulmonary Disease, Chronic Obstructive
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese Subjects
GW642444 is a potent and selective long-acting beta2 agonist; GSK573719 is a long-acting, inhaled, muscarinic receptor antagonist (or anticholinergic) bronchodilator.
- Trial name
- DB2113208 (NCT00976144)
- Testing
- GSK573719
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Emphysema
Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)
The purpose of this study is to demonstrate the safety and efficacy of AeriSeal System treatment plus optimal medical therapy compared in patients with advanced upper lobe predominant (ULP) heterogeneous emphysema.
- Trial name
- ASPIRE (NCT01449292)
- Testing
- Treatment plus Optimal Medical Therapy, Optimal Medical Therapy
- Where
- 40 sites in United States, France and 5 more
- Volunteers
- 300 people
- Sponsor
- Aeris Therapeutics
COPD
A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD
The purpose of this study is to determine the safety and efficacy of the investigational drug in comparison with a placebo.
- Trial name
- NCT00215436
- Testing
- Formoterol Fumarate
- Where
- 44 sites in United States
- Volunteers
- 345 people
- Sponsor
- Dey
Chronic Obstructive Pulmonary Disease
Safety, Preliminary Pharmacokinetics and Bronchodilator Properties of V0162
Pulmonary administered anticholinergic agents have shown their importance in the chronic obstructive pulmonary disease (COPD) management to reduce morbidity, disability and mortality.
- Trial name
- NCT01348555
- Testing
- Bronchodilatator
- Where
- 2 sites in Belgium, France
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Medicament
Pulmonary Disease, Chronic Obstructive
Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.
Post marketing Surveillance to gain insights into the effects of therapy with Spiriva® (tiotropium bromide) on health-related quality of life in COPD patients who stopped smoking during treatment and to obtain safety data…
- Trial name
- NCT02172547
- Testing
- Spiriva
- Volunteers
- 10,821 people
- Sponsor
- Boehringer Ingelheim
Asthma,, Chronic Obstructive Pulmonary Disease
Observational Study to Evaluate the Correctness of the Use of Inhaler Device in Patients With Asthma or Chronic Obstruct
The correct use of inhalation devices is an inclusion criterion for all studies comparing inhaled treatments. In real life, however, patients may make many errors with their usual inhalation device, which may negate the benefits…
- Trial name
- NCT01426893
- Where
- 5 sites in Serbia
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD
Non-inferiority of lung function response to Tiotropium inhalation solution compared to Spiriva HandiHaler
- Trial name
- NCT00239447
- Testing
- Tiotropium, HandiHaler, Respimat SMI
- Where
- 11 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- Boehringer Ingelheim
COPD, COPD Bronchitis
NBMI - Clinical Study on COPD
A pilot study to explore safety of the treatment with the antioxidant and metal chelator NBMI in COPD patients. Investigational product: NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide), INN: Emeramide Indication: Mild, moderate…
- Trial name
- Emera003COPD (NCT03123692)
- Testing
- Emeramide
- Volunteers
- 12 people
- Sponsor
- EmeraMed
Pulmonary Disease, Chronic Obstructive
Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease
Relatively little information is available about the effects of salmeterol/fluticasone combination and fluticasone alone in COPD patients with a partial reversible pulmonary obstruction.
- Trial name
- NCT00549146
- Testing
- fluticasone propionate/salmeterol 250/50 DISKUS combination product, fluticasone propionate DISKUS 500mcg
- Where
- 17 sites in Netherlands
- Volunteers
- 290 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease, COPD
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)
The purpose of this study is to investigate the effect of 500mcg roflumilast vs placebo on exacerbation rate and pulmonary function as well as quality of life in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00430729
- Testing
- Roflumilast
- Where
- 14 sites in Australia, Austria and 12 more
- Volunteers
- 1,100 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients
The main purpose of this study is to assess the long term bronchodilator efficacy, safety and tolerability of inhaled aclidinium bromide at two dose levels compared to placebo in COPD patients and the benefits of the product in…
- Trial name
- NCT01001494
- Testing
- Aclidinium bromide 200 μg bid, Aclidinium bromide 400 μg bid
- Where
- 106 sites in Czechia, France and 9 more
- Volunteers
- 828 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency
ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study
The purpose of this study is to evaluate the efficacy of ARALAST NP A1PI augmentation therapy 120 milligrams per kilogram (mg/kg) body weight (BW)/week compared with an external placebo comparator on the loss of emphysematous…
- Trial name
- NCT04440488
- Testing
- ARALAST NP
- Sponsor
- Shire
Chronic Obstructive Pulmonary Disease (COPD)
Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination
The objective is to provide data supporting the use of LAS40464 as an efficacious and safe maintenance bronchodilator treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT01462942
- Testing
- Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate
- Where
- 197 sites in Austria, Belgium and 20 more
- Volunteers
- 2,443 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
The primary objective was to compare the bronchodilator efficacy of two doses (5 mcg and 10 mcg) of tiotropium inhalation solution delivered by the Respimat inhaler once daily to placebo and to ipratropium bromide MDI four times…
- Trial name
- NCT00239473
- Testing
- 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler, 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler
- Where
- 38 sites in Germany, Italy and 2 more
- Volunteers
- 429 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
This study assessed the efficacy and safety of indacaterol (150 µg once daily [od]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease…
- Trial name
- INTRUST2 (NCT00877383)
- Testing
- Indacaterol 150 μg, Tiotropium 18 μg
- Where
- 176 sites in United States, Canada and 7 more
- Volunteers
- 1,142 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease, Emphysema
Endobronchial Valve for Emphysema Palliation Trial (VENT)
The purpose of this study is to assess the safety and efficacy of the Emphasys Endobronchial Valve (EBV) and procedure (with pulmonary rehabilitation) compared to optimal medical management (with pulmonary rehabilitation) in…
- Trial name
- NCT00129584
- Testing
- Emphasys Endobronchial Valve and procedure
- Volunteers
- 270 people
- Sponsor
- Emphasys Medical
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD
This is a randomised, controlled, two period cross-over, 4 weeks chronic dosing, study to evaluate the effects of Budesonide/Glycopyrronium/Formoterol Fumarate (BGF) and Glycopyrronium/Formoterol Fumarate (GFF) on airway…
- Trial name
- NCT03836677
- Testing
- BGF, GFF
- Where
- 4 sites in Belgium, Netherlands
- Volunteers
- 23 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Burden of Disease Among Subjects With Eosinophilic Chronic Obstructive Pulmonary Disease (COPD)
This observational study is designed to more specifically describe the burden of the disease and the use of healthcare resources of subjects with eosinophilic COPD that may be eligible in the future for a biologic treatment.
- Trial name
- NCT03436511
- Where
- 4 sites in Spain
- Volunteers
- 341 people
- Sponsor
- GlaxoSmithKline
COPD Method Evaluation, Chronic Obstructive Pulmonary Disease Method Evaluation
Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler
The main purpose of this study is to evaluate the sensitivity of a new oxygen enhanced magnetic resonance imaging (OE-MRI) method in detecting changes in the lungs of patients with moderate to severe chronic obstructive pulmonary…
- Trial name
- NCT01257048
- Testing
- Formoterol Turbuhaler, Budesonide/Formoterol Turbuhaler
- Where
- 2 sites in Sweden, United Kingdom
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This study will evaluate the onset of action of indacaterol (150 and 300 µg) as compared to placebo, salbutamol 200 µg and salmeterol/fluticasone 50/500 µg
- Trial name
- NCT00669617
- Testing
- Indacaterol, Salmeterol/fluticasone (50/500 μg), Salbutamol (200 µg)
- Where
- 17 sites in United States, Belgium and 2 more
- Volunteers
- 89 people
- Sponsor
- Novartis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.